http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102805747-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a79280a523e3b0000e8de82f2e77698 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33e7126a92ad662638d48581e685d613 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5fdcd0e05ed0d151491af984cf6fea7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71cd12c9e4ed242775138c309dd66bd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b74203cf26ca663f365ace52a0815d5 |
| publicationDate | 2013-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102805747-B |
| titleOfInvention | Use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine in pharmacy |
| abstract | The invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative of the 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine. The chemical compound can inhibit the synthesis of activated hepatic stellate cells, the synthesis and expression of superficial collagen and other extracellular matrix proteins, including MMPs (matrix metalloproteinases) and TIMPs (tissue inhibitor of matrix metalloproteinases), and the hepatic fibrosis; the chemical compound can inhibit the synthesis and expression of the collagen in human bodies, so as to reverse and treat hepatitis and the hepatic fibrosis; and the chemical compound can be used independently or in conjunction with targeted molecules or carriers, including vitamin A-coupled liposome, so as to be prepared into drugs for treating or preventing the infectious hepatitis, non-infectious hepatitis, hepatic injury, cirrhosis, liver cancers and hepatic fibrosis, and protecting or improving liver functions. |
| priorityDate | 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.